Bilgen Ekim
@bilgenekim.bsky.social
PhD, Research Group Leader at Helmholtz Diabetes Center IDC & Heidelberg University Hospital, Germany.
https://tinyurl.com/2p949c9z
https://tinyurl.com/2p949c9z
Our latest study in pancreatic beta cells is published!👏
We identified TSC22D1 protein as a downstream target of glucose signaling and a novel regulator of beta cell function.
Congrats to the first author Dr.Yıldırım and many thanks to all coauthors!
febs.onlinelibrary.wiley.com/doi/10.1111/...
We identified TSC22D1 protein as a downstream target of glucose signaling and a novel regulator of beta cell function.
Congrats to the first author Dr.Yıldırım and many thanks to all coauthors!
febs.onlinelibrary.wiley.com/doi/10.1111/...
FEBS Press
TSC22D1 acts downstream of glucose signaling and negatively regulates insulin secretion in pancreatic beta cells. Mechanistically, TSC22D1 interacts with FoxO1. Elevated glucose levels enhance the TS....
febs.onlinelibrary.wiley.com
July 22, 2025 at 4:33 PM
Our latest study in pancreatic beta cells is published!👏
We identified TSC22D1 protein as a downstream target of glucose signaling and a novel regulator of beta cell function.
Congrats to the first author Dr.Yıldırım and many thanks to all coauthors!
febs.onlinelibrary.wiley.com/doi/10.1111/...
We identified TSC22D1 protein as a downstream target of glucose signaling and a novel regulator of beta cell function.
Congrats to the first author Dr.Yıldırım and many thanks to all coauthors!
febs.onlinelibrary.wiley.com/doi/10.1111/...
Personalized in vivo Crispr therapy for a rare genetic disorder - just in 6 months 👏👏
A lipid nanoparticle–delivered base-editing therapy was custom designed for an infant with a ureacycle disorder. The affected infant was treated at approximately 7 and 8 months of age. Read the Brief Report: nej.md/42XF03F
#ASGCT2025 #MedSky @asgct.bsky.social
#ASGCT2025 #MedSky @asgct.bsky.social
Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease | NEJM
Base editors can correct disease-causing genetic variants. After a neonate had received
a diagnosis of severe carbamoyl-phosphate synthetase 1 deficiency, a disease with
an estimated 50% mortality ...
nej.md
May 15, 2025 at 8:27 PM
Personalized in vivo Crispr therapy for a rare genetic disorder - just in 6 months 👏👏